Overview

A Study in Healthy People to See How Zongertinib is Taken up Into the Blood When Given as Tablets Made by Two Different Manufacturers

Status:
COMPLETED
Trial end date:
2024-07-15
Target enrollment:
Participant gender:
Summary
The main objective of this trial is to establish the bioequivalence of zongertinib tablet from manufacturer 1 (Test, T) compared with zongertinib tablet from manufacturer 2 (reference, R) following oral administration.
Phase:
PHASE1
Details
Lead Sponsor:
Boehringer Ingelheim